Additionally, a report detailed the efficacy of monthly intravenous QBX258 infusion, a combination of two monoclonal antibodies neutralizing IL-4 and IL-13, in eight patients with breast cancer-related lymphedema [28]. This evidence concerns the gene IL4 and lymphedema.